News Release

New Orleans, LA, December 7, 2013 – Millennium: The Takeda Oncology Company with its parent company, Takeda Pharmaceutical Company Limited (TSE:4502), today announced results from a retrospective, subgroup analysis of the Phase 3 VISTA study that showed a higher cumulative dose of VELCADE® (bortezomib) suggests improved overall survival (OS) in previously untreated patients with multiple myeloma (MM) (hazard ratio [HR] 0.53; p<0.0001). Patients who received a cumulative dose of VELCADE of 39 mg/m2 or greater lived 20 months longer on average than those who received lower cumulative doses (median OS 66.3 months and 46.2 months, respectively). The subgroups were determined post-randomization and the analysis was retrospective.

The retrospective analysis was conducted using data from the VISTA study, which evaluated the safety and efficacy of a VELCADE-melphalan-prednisone (VMP) regimen of up to 54 weeks compared with melphalan-prednisone (MP) alone in patients with previously untreated MM. These data were presented today at the 55th American Society of Hematology (ASH) annual meeting held in New Orleans, LA on December 7-10, 2013.

"VISTA showed an overall survival benefit in multiple myeloma and it reinforces the importance of treating patients with a twelve-month course of VELCADE therapy,” said María-Victoria Mateos, MD, University Hospital of Salamanca, Salamanca, Spain. "This subgroup analysis, while retrospective, suggests that patients who received a dose of 39 mg/m2 or greater fared better than those who received a lesser dose."

VELCADE is approved by the U.S. Food & Drug Administration (FDA) for the treatment of MM and relapsed mantle cell lymphoma (MCL).

“Ten years after its introduction, VELCADE continues to make a difference in the lives of patients with multiple myeloma,” said Michael Vasconcelles, MD, Head, Oncology Therapeutic Area Unit, Takeda Pharmaceutical Company. “As we work to discover and bring new therapies to patients, we are also committed to helping patients get the most out of the treatments currently available.”

The poster presentation featured a retrospective, subgroup analysis of data from the VMP arm of the Phase 3 VISTA study that examined whether increased cumulative bortezomib dosing (total dosing received during the study) led to improved long-term outcomes. The VISTA study evaluated VMP vs. MP in transplant-ineligible patients with previously untreated MM in terms of response rates, time to progression (primary endpoint), and OS. The subgroups analyzed were determined post-randomization. The VMP subgroup analysis was presented by María-Victoria Mateos, MD, who reported the following:

The median cumulative dose in the overall VISTA trial was 39 mg/m2. The median treatment durations were 2.5 months (range, 0.1 to 13.9) for patients receiving less than 39 mg/m2 and 12.1 months (range, 5.2 to 13.9) for patients receiving 39 mg/m2 or greater. Some patients could continue MP treatment after stopping VELCADE, so the maximum values are 13.9 for both.

As with all retrospective analyses, these data do not warrant the same merit as a prospective randomized trial.

Patients (n=340) treated with the VMP regimen in VISTA received up to nine six-week cycles (up to 54 weeks) of the combination therapy (cycles 1-4: VELCADE 1.3 mg/m2 IV, days 1, 4, 8, 11, 22, 25, 29, 32; cycles 5-9: VELCADE 1.3 mg/m2 IV, days 1, 8, 22, 29; all cycles: melphalan 9 mg/m2 and prednisone 60 mg/m2). The maximum planned dose of VELCADE was 67.6 mg/m2, including 41.6 mg/m2 during cycles 1-4 and 26 mg/m2 during cycles 5-9. The median cumulative VELCADE dose received was 39 mg/m2, which was selected as the cut-off point for defining patient groups by cumulative VELCADE dose for analyses of OS. A landmark analysis of OS from 180 days after the first dose to approximately align with cycles 1-4 of the study was conducted.

About VELCADE® VELCADE® (bortezomib) is co-developed by Millennium/Takeda and Janssen Pharmaceutical Companies. Millennium is responsible for commercialization of VELCADE in the U.S.; Janssen Pharmaceutical Companies are responsible for commercialization in Europe and the rest of the world. Takeda Pharmaceutical Company Limited and Janssen Pharmaceutical K.K. co-promote VELCADE in Japan. VELCADE is approved in more than 90 countries and has been used to treat more than 450,000 patients worldwide.

VELCADE: Important Safety Information
VELCADE® (bortezomib) is approved for the treatment of patients with multiple myeloma. VELCADE is also approved for the treatment of patients with mantle cell lymphoma who have already received at least one prior treatment.

Patients should not receive VELCADE if they are allergic to bortezomib, boron or mannitol. VELCADE should not be administered intrathecally. Women should avoid becoming pregnant or breastfeeding while taking VELCADE. Patients with diabetes may require close monitoring and adjustment of their medication.

VELCADE can cause serious side effects, including:

Peripheral neuropathy. Nerve problems, which can be severe including muscle weakness, tingling, burning, pain, or loss of feeling in the hands and feet.

Heart problems.Heart rhythm problems and heart failure including worsening of existing conditions. Symptoms may include chest pressure or pain, palpitations, swelling of the ankles or feet, or shortness of breath.

Lung problems, some of which have been fatal. Symptoms include cough, shortness of breath, wheezing or difficulty breathing.

Liver problems.Liver failure including a yellow discoloration of the eyes and skin.

These are not all of the possible side effects with VELCADE. Please see the full Prescribing Information for VELCADE for a complete list available at VELCADE.com.

# # #

About Takeda
Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, www.takeda.com.

You Are Leaving Takeda Oncology

You are now leaving takedaoncology.com. Links to sites outside of takedaoncology.com are provided as a resource to the viewer. takedaoncology.com accepts no responsibility for the linked sites that takedaoncology.com has no control over.

Interacting with Takeda Oncology on Social Media

Definition of Social Media

Takeda Oncology recognizes the importance of social media channels in the communication space. However, in embracing these channels, we aim to engage responsibly. Below, we have outlined our current active channels as well our terms and guidelines for interacting with us on these channels. Current channels in which Takeda Oncology participates:

Other services may be added. Check back occasionally to see all of the channels we support.

These channels were created and are managed by Takeda Oncology. Their purpose is to educate the public about our company, mission, values as well as the diseases we aspire to cure and the populations we serve. The content posted by Takeda Oncology is for informational and educational purposes only and is NOT intended to be a substitute for professional medical advice.

Mentions, comments, likes, favorites and retweets are welcomed! However, please note, the pharmaceutical industry is a highly regulated one and as a result we may not be allowed to respond to "@mentions" and replies that:

Please note that accounts that Takeda Oncology follows/interacts with or accounts that follow/interact with us on our various channels are not an indication of Takeda Oncology's endorsement of these accounts or the content they produce. Additionally, favorites, likes, comments and/or retweets do not indicate endorsement.

Takeda Oncology may provide links or references to other websites as part of its social content. We claim no responsibility for the accuracy or content of such other sites and shall not be liable for any damages or injury arising from that content.

Please do not use these channels to report adverse events or medical side effects. If you believe that you have experienced any medical side effects or reactions from a Takeda Oncology product you should consult your physician, pharmacist or other healthcare professional immediately. You can also report these to us directly by calling us here: 1-877-TAKEDA7.

We will do our best to answer your comments and questions; however, there may be some things we cannot address, such as questions directly related to financial, legal, regulatory, confidential information, or medical issues. In scenarios when Takeda Oncology cannot post or respond to your comment, we will send a private message to you explaining why.

Thank you for your interest in connecting with us on social media — we look forward to hearing from you and sharing more about our work in the fight against cancer.

DISCLAIMER

Takeda Oncology does not endorse any user or associated products and services of any social media user that interacts with our profiles. Takeda Oncology may link to an external website for interest or convenience. Takeda Oncology claims no responsibility for the content of sites over which we have no control, and are not liable for any damages or injury arising from that content. Takeda Oncology reserves all rights relating to our social media profiles and properties, including discontinuing the Page, removing unwanted connections, responding to any questions or comments, and removing or modifying any content posted to the profile.